February 1, 2017 / 5:21 PM / in 9 months

BUZZ-U.S. STOCKS ON THE MOVE-Apple, AMD, Pitney Bowes, Anthem

* Eikon search string for individual stock moves: STXBZ

* The Day Ahead newsletter: tmsnrt.rs/2ggOmBi

* The Morning News Call newsletter: tmsnrt.rs/2fwPLTh The S&P 500 slipped into the red and the Dow pared gains in late morning trade on Wednesday, led by losses in energy and utilities sectors, ahead of the Federal Reserve's decision on interest rates.

The Dow Jones Industrial Average was unchanged at 19,864.74, the S&P 500 was down 0.16 percent at 2,275.25 and the Nasdaq Composite was up 0.27 percent at 5,629.768.

** APPLE INC, $128.72, +6.07 pct

The iPhone maker reclaimed the throne as the world’s top smartphone seller for the first time in five years on Tuesday, beating out rival Samsung in units shipped for the holiday quarter and boosting revenues with a strong showing for its new, top-of-the-line iPhone 7 Plus.

BREAKINGVIEWS-Apple working harder to squeeze iPhone juice

** ADVANCED MICRO DEVICES INC, $11.80, +13.74 pct

The chipmaker posted a smaller-than-expected quarterly loss and gave a strong revenue forecast for the current quarter, boosted by demand for its graphic chips used in gaming consoles and a stabilizing PC market.

** PITNEY BOWES INC, $13.15, -17.40 pct

The company, which makes postage meters and other mail equipment, reported Q4 revenue, profit that missed analysts’ estimates. The company blamed non-completion of several anticipated deals in past few weeks of Q4, and poor performance of its software business.

** ONEOK PARTNERS, $51.49, +19.36 pct

** ONEOK INC, $53.45, -3.01 pct

The natural gas pipeline company said it would buy the remainder of Oneok Partners for $9.3 billion, adding to a string of master limited partnerships deals aimed at simplifying structures and increasing returns.

** ANTHEM INC, $156.80, +1.73 pct

The no. 2 U.S. health insurer, which is fighting a U.S. government lawsuit to block its deal to buy Cigna Corp, it expected to break even or make a small profit in the Obamacare individual market in 2017 even as it considers pulling out of that business next year.

** ARCONIC INC, $24.82, +9.19 pct

Activist investor Elliott Management on Tuesday launched a proxy fight against Arconic Inc, which makes engineered metal parts for the aerospace, automotive and other industries, campaigning for the ouster of the company’s chief executive and saying it had a plan to boost the company’s performance.

** CATABASIS PHARMACEUTICALS INC, $1.19, -70.54 pct

The drug developer’s DMD drug failed to meet the primary goal in part B of MoveDMD trial.

** MATCH GROUP INC, $16.68, -3.97 pct

The dating website operator’s Q4 revenue missed analysts’ average estimate.

** JOHNSON CONTROLS INTERNATIONAL PLC, $42.46, -3.46 pct

The multi-industry U.S. manufacturer’s quarterly organic sales growth fell short of its estimate, hurt by weakness in its biggest business, and the multi-industry U.S. manufacturer forecast current-quarter earnings below Wall Street expectations.

** SANCHEZ ENERGY CORP, $12.56, -5.28 pct

The oil producer is offering 10 million shares, about 5.7 percent discount to the stock’s last close. Blackstone-affiliate GSO Capital Partners to purchase 500,000 shares.

** VERICEL CORP, $2.70, +3.85 pct

The stem cell therapy maker said that the first patient in the United States had received its MACI implant for cartilage defects of the knee with or without bone involvement for adults.

** CAMECO CORP, $11.18, -12.31 pct

Tokyo Electric Power (Tepco), the operator of Japan’s wrecked Fukushima nuclear plant, scrapped a uranium supply contract with the Canadian uranium producer.

** SYNERGY PHARMACEUTICALS, $6.07, -14.19

The drugmaker announced a public offering of $125 million common shares.

** CERULEAN PHARMA INC, $0.82, +0.62 pct

The drug developer’s board said it is conducting review of strategic alternatives.

** REAL GOODS SOLAR INC, $3.21, -17.05 pct

The solar company’s priced public offering of common stock at $11.5 million.

** GALENA BIOPHARMA INC, $1.29, -21.82 pct

The oncology drug developer entered into a “separation agreement” with Chief Executive Mark Schwartz, who will resign immediately, and announced that the company was exploring strategic alternatives, including a sale.

** OVERSTOCK.COM INC, $19.26, +16.02 pct

The online retailer posted Q4 revenue above analysts’ average estimate of $523.49 million.

** MANHATTAN ASSOCIATES INC, $47.11, -8.10 pct

The supply chain management software maker’s Q4 revenue missed Wall Street estimates and also forecasted FY17 revenue below analysts’ average estimate.

** BANCORP INC, $5.20, -13.19 pct

Brokerage Raymond James downgraded the bank’s stock, citing potential need to raise capital.

** SUMMIT THERAPEUTICS PLC, $11.88, +13.51 pct

The drug developer said it intended to design late-stage trial for its experimental drug, ridinilazole, after meeting with U.S. Food and Drug Administration and European Medicines Agency.

** COSTAMARE INC, $5.52, +3.95 pct

Brokerage Morgan Stanley upgraded the marine transportation services provider’s stock to “overweight” and cut its PT to $7 from $8.

** FLUSHING FINANCIAL CORP, $28.02, +3.01 pct

The bank posted Q4 EPS of 50 cents vs Street estimate of 49 cents per share.

** PACIFIC COAST OIL TRUST, $1.44, +21.01 pct

The oil producer said it would restart distribution payouts. The company also said its existence beyond 2017 is assured since it expects net profits and royalties in 2017 to exceed $2 million of proceeds received attributable to the conveyed interests. (Compiled by Ahmed Farhatha in Bengaluru; Editing by Sriraj Kalluvila)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below